Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions

Vaccine

Volumn 26, Issue SUPPL. 10, 2008, Pages

  Giuliano, Anna R ^a   Tortolero Luna, Guillermo ^b   Ferrer, Elena ^c   Burchell, Ann N ^d   de Sanjose, Silvia ^c,e   Kjaer, Susanne Kruger ^f   Muñoz, Nubia ^c,g   Schiffman, Mark ^h   Bosch, F Xavier ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d MCGILL UNIVERSITY   (Canada)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^g Instituto Nacional de Cancerología   (Colombia)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anogenital cancer; Cancer; Genital warts; HPV; Infection; Men; Respiratory papillomatosis; Women

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; CANCER INCIDENCE; CANCER RISK; CIGARETTE SMOKING; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; GENITAL TRACT CANCER; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; LARYNX CANCER; MALE; MOUTH CANCER; NONHUMAN; ORAL CONTRACEPTION; PENIS CANCER; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY PAPILLOMATOSIS; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VIRUS DETECTION; VIRUS INFECTION; VIRUS TYPING; VULVA CANCER; WART VIRUS;

ANUS NEOPLASMS; CONDYLOMATA ACUMINATA; FEMALE; GENITAL DISEASES, MALE; GENITAL NEOPLASMS, MALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; UTERINE CERVICAL DISEASES;

EID: 50849099522     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.021     Document Type: Article

References (91)

1. IARC. Human Papillomavirus. IARC Monographs on the Evaluation of carcinogenic risk to humans. Vol. 90. Lyon: IARC Press, 2007.
2. Haga T., Kim S.H., Jensen R.H., Darragh T., and Palefsky J.M. Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr 26 3 (2001) 256-262
3. Palefsky J.M. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J Natl Cancer Inst Monogr 23 (1998) 15-20
4. Palefsky J.M., Holly E.A., Ralston M.L., Da Costa M., and Greenblatt R.M. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 183 3 (2001) 383-391
5. Xi L.F., Critchlow C.W., Wheeler C.M., Koutsky L.A., Galloway D.A., Kuypers J., et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res 58 17 (1998) 3839-3844
6. Critchlow C.W., Hawes S.E., Kuypers J.M., Goldbaum G.M., Holmes K.K., Surawicz C.M., et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS 12 10 (1998) 1177-1184
7. Munoz N., Castellsague X., Bosch F.X., Tafur L., de Sanjose S., Aristizabal N., et al. Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. J Natl Cancer Inst 88 15 (1996) 1068-1075
8. Castellsague X., Bosch F.X., Munoz N., Meijer C.J., Shah K.V., de Sanjose S., et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 346 15 (2002) 1105-1112
9. Castellsague X., Ghaffari A., Daniel R.W., Bosch F.X., Munoz N., and Shah K.V. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis 176 2 (1997) 353-361
10. Kreimer A.R., Clifford G.M., Boyle P., and Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 2 (2005) 467-475
11. Giuliano A.R., Nielson C.M., Flores R., Dunne E.F., Abrahamsen M., Papenfuss M.R., et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis 196 8 (2007) 1146-1152
12. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., and Giuliano A.R. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 194 8 (2006) 1044-1057
13. Nielson C.M., Flores R., Harris R.B., Abrahamsen M., Papenfuss M.R., Dunne E.F., et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 16 6 (2007) 1107-1114
14. Weaver B.A., Feng Q., Holmes K.K., Kiviat N., Lee S.K., Meyer C., et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 189 4 (2004) 677-685
15. Flores R., Abalos A.T., Nielson C.M., Abrahamsen M., Harris R.B., and Giuliano A.R. Reliability of sample collection and laboratory testing for HPV Detection in Men. J Virol Methods 149 1 (2008) 136-143
16. Giuliano AR, Lu B, Nielson C, et al. Age Specific Prevalence, Incidence, and Duration of Human Papillomavirus Infections Among a Cohort of 290 US Men. J Infect Dis. 2008, in press.
17. Nielson CM, Dunne EF, Abrahamsen M, Harris R, Giuliano AR. Associations between male anogenital HPV infection and circumcision vary by anatomic site sample. Abstract PS8-44. 24th International Papillomavirus Conference and Clinical Workshop. Beijing, China, November 2007. (Abstracts book).
18. Giuliano AR, Lazcano E, Villa LL, et al. Factors associated with HPV detection among men internationally: The HIM Study. Abstract 8B-04 24th International Papillomavirus Conference and Clinical Workshop. Beijing, China, November 2007. (Abstracts book).
19. Giuliano AR, Lazcano E, Villa LL, et al. The Human Papillomavirus Infection in Men (HIM) Study: HPV Prevalence and Type-Distribution among Men Residing in Brazil, Mexico, and the US. Cancer Epidemiol Biomarkers Prev. 2008, in press.
20. Kyo S., Inoue M., Koyama M., Fujita M., Tanizawa O., and Hakura A. Detection of high-risk human papillomavirus in the cervix and semen of sex partners. J Infect Dis 170 3 (1994) 682-685
21. Campion M.J., Singer A., Clarkson P.K., and McCance D.J. Increased risk of cervical neoplasia in consorts of men with penile condylomata acuminata. Lancet 1 8435 (1985) 943-946
22. Partridge J.M., Hughes J.P., Feng Q., Winer R.L., Weaver B.A., Xi L.F., et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 196 8 (2007) 1128-1136
23. Giuliano A.R., Harris R., Sedjo R.L., Baldwin S., Roe D., Papenfuss M.R., et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis 186 4 (2002) 462-469
24. Van Doornum G.J., Prins M., Juffermans L.H., Hooykaas C., van den Hoek J.A., Coutinho R.A., et al. Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourin Med 70 4 (1994) 240-246
25. Svare E.I., Kjaer S.K., Nonnenmacher B., Worm A.M., Moi H., Christensen R.B., et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 176 4 (1997) 876-883
26. Slavinsky III J., Kissinger P., Burger L., Boley A., DiCarlo R.P., and Hagensee M.E. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 12 8 (2001) 516-523
27. Hagensee M.E., Koutsky L.A., Lee S.K., Grubert T., Kuypers J., Kiviat N.B., et al. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis 181 4 (2000) 1234-1239
28. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 9574 (2007) 1693-1702
29. Sankaranarayanan R., and Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20 2 (2006) 207-225
30. Rotmensch J, Yamada SD. Neoplasms of the Vulva and Vagina. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast JrR, Gansler TSHJFea, editors. Holland-Frei Cancer Medicine. 6th ed. Hamilton, Ontario: B.C. Decker, Inc, 2003.
31. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute, 2003.
32. Van Seters M., Van Beurden M., and de Craen A.J. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 97 2 (2005) 645-651
33. Jones R.W., Rowan D.M., and Stewart A.W. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 106 6 (2005) 1319-1326
34. Srodon M., Stoler M.H., Baber G.B., and Kurman R.J. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 30 12 (2006) 1513-1518
35. Sideri M, Jones RW, Heller DS, Haefner H, Neill S, Preti M, et al. Comment on the Article: Srodon M, Stoler MH, Baber GB, et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN) Am J Surg Pathol. 2006; 30:1513-1518. Am J Surg Pathol 2007; 31(9):1452-4.
36. Sideri M., Jones R.W., Wilkinson E.J., Preti M., Heller D.S., Scurry J., et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 50 11 (2005) 807-810
37. Scurry J., Campion M., Scurry B., Kim S.N., and Hacker N. Pathologic audit of 164 consecutive cases of vulvar intraepithelial neoplasia. Int J Gynecol Pathol 25 2 (2006) 176-181
38. Jones R.W. Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol Oncol 22 6 (2001) 393-402
39. Skapa P., Zamecnik J., Hamsikova E., Salakova M., Smahelova J., Jandova K., et al. Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am J Surg Pathol 31 12 (2007) 1834-1843
40. Judson P.L., Habermann E.B., Baxter N.N., Durham S.B., and Virnig B.A. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107 5 (2006) 1018-1022
41. Madeleine M.M., Daling J.R., and Tamimi H.K. Vulva and Vagina. In: Franco E.L., and Rohan T.E. (Eds). Cancer Precursors: Epidemiology, Detection, and Prevention (2002), Springer-Verlag, New York 321-332
42. Howe H.L., Wingo P.A., Thun M.J., Ries L.A., Rosenberg H.M., Feigal E.G., et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93 11 (2001) 824-842
43. Cancer Research UK. www.cancerresearchuk.org; Available at: www.cancerresearchuk.org. (last accessed: April 2008).
44. Kosary C.L. Cancer of the Vulva. In: Ries L.A.G., Young J.L., Keel G.E., Eisner M.P., Lin Y.D., and Horner M.-J. (Eds). SEER survival monograph: Cancer survival among adults: US SEER Program 1998-2001, Patient and Tumor Characteristics (2007), National Cancer Institute, NIH, Bethesda, MD
45. Kurman R.J., Toki T., and Schiffman M.H. Basaloid and warty carcinomas of the vulva. Distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol 17 2 (1993) 133-145
46. Trimble C.L., Hildesheim A., Brinton L.A., Shah K.V., and Kurman R.J. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol 87 1 (1996) 59-64
47. Leibowitch M., Neill S., Pelisse M., and Moyal-Baracco M. The epithelial changes associated with squamous cell carcinoma of the vulva: a review of the clinical, histological and viral findings in 78 women. Br J Obstet Gynaecol 97 12 (1990) 1135-1139
48. Nascimento C, Clifford G, DeVuyst H, Franceschi S. HPV prevalence and type distribution in carcinomas and intraepithelial neoplasia lesions of the vulva and vagina. The first in a series of meta-analysis in anogenital sites other than cervix. Abstract 4B-01. 24th International Papillomavirus Conference and Clinical Workshop. Beijing, China, November 2007. (Abstracts book).
49. Bosch FX, Vallès X, Muñoz N, Alejo M, Klaustermeier J, Lloveras B, et al. HPV contribution and genotype distribution in invasive cancer of the vulva and the vagina in 14 countries. Abstract PA2-06. 24th International Papillomavirus Conference and Clinical Workshop. Beijing, China, November 2007. (Abstracts book).
50. Hildesheim A., Han C.L., Brinton L.A., Kurman R.J., and Schiller J.T. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol 90 5 (1997) 748-754
51. Madeleine M.M., Daling J.R., Carter J.J., Wipf G.C., Schwartz S.M., McKnight B., et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 89 20 (1997) 1516-1523
52. Parkin DM, Whelan SLFJ, Teppo L, Thomas DB. Cancer Incidence in Five Continents, Volume VIII. Lyon: IARC Scientific Publications No. 155, 2003.
53. Levi F., Randimbison L., and La Vecchia C. Descriptive epidemiology of vulvar and vaginal cancers in Vaud, Switzerland, 1974-1994. Ann Oncol 9 11 (1998) 1229-1232
54. Kosary CL. Cancer of the Vagina. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, editors. SEER survival monograph: Cancer survival among adults: US SEER Program 1998-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, NIH, 2007.
55. Daling J.R., Sherman K.J., Hislop T.G., Maden C., Mandelson M.T., Beckmann A.M., et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 135 2 (1992) 180-189
56. Daling J.R., Madeleine M.M., Schwartz S.M., Shera K.A., Carter J.J., McKnight B., et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 84 2 (2002) 263-270
57. Brinton L.A., Reeves W.C., Brenes M.M., Herrero R., de Britton R.C., Gaitan E., et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol 19 1 (1990) 4-11
58. Carter J.J., Madeleine M.M., Shera K., Schwartz S.M., Cushing-Haugen K.L., Wipf G.C., et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 61 5 (2001) 1934-1940
59. Brinton L.A., Nasca P.C., Mallin K., Schairer C., Rosenthal J., Rothenberg R., et al. Case-control study of in situ and invasive carcinoma of the vagina. Gynecol Oncol 38 1 (1990) 49-54
60. Daling J.R., and Sherman K.J. Cancer of the vulva and vagina. In: Schottenfeld D., and Fraumeni (Eds). Cancer Epidemiology and Prevention (1996), Oxford University Press, New York 1117-1129
61. Daling J.R., Madeleine M.M., Johnson L.G., Schwartz S.M., Shera K.A., Wurscher M.A., et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101 2 (2004) 270-280
62. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006 21;24 (Suppl. 3):S11-S25.
63. Varnai A.D., Bollmann M., Griefingholt H., Speich N., Schmitt C., Bollmann R., et al. HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. Int J Colorectal Dis 21 2 (2006) 135-142
64. IARC. Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No.160. Lyon: IARC, 2007.
65. Micali G., Nasca M.R., Innocenzi D., and Schwartz R.A. Penile cancer. J Am Acad Dermatol 54 3 (2006) 369-391
66. Hoffman H.T., Karnell L.H., Funk G.F., Robinson R.A., and Menck H.R. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg 124 9 (1998) 951-962
67. Sturgis E.M., and Cinciripini P.M. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?. Cancer 110 7 (2007) 1429-1435
68. Soares R.C., Oliveira M.C., Souza L.B., Costa A.L., Medeiros S.R., and Pinto L.P. Human papillomavirus in oral squamous cells carcinoma in a population of 75 Brazilian patients. Am J Otolaryngol 28 6 (2007) 397-400
69. Pintos J., Black M.J., Sadeghi N., Ghadirian P., Zeitouni A.G., Viscidi R.P., et al. Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada. Oral Oncol 44 3 (2008) 242-250
70. D'Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 19 (2007) 1944-1956
71. Herrero R., Castellsague X., Pawlita M., Lissowska J., Kee F., Balaram P., et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95 23 (2003) 1772-1783
72. Maw R.D., Reitano M., and Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 9 10 (1998) 571-578
73. Friis S., Kjaer S.K., Frisch M., Mellemkjaer L., and Olsen J.H. Cervical intraepithelial neoplasia, anogenital cancer, and other cancer types in women after hospitalization for condylomata acuminata. J Infect Dis 175 4 (1997) 743-748
74. Lacey C.J., Lowndes C.M., and Shah K.V. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 Suppl 3 (2006 Aug 21) S35-S41
75. Fenton K.A., Korovessis C., Johnson A.M., McCadden A., McManus S., Wellings K., et al. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet 358 9296 (2001) 1851-1854
76. Grulich A.E., de Visser R.O., Smith A.M., Rissel C.E., and Richters J. Sex in Australia: knowledge about sexually transmissible infections and blood-borne viruses in a representative sample of adults. Aust N Z J Public Health 27 2 (2003) 230-233
77. Dinh T.H., Sternberg M., Dunne E.F., and Markowitz L.E. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 35 4 (2008 Apr) 357-360
78. Kjaer S.K., Tran T.N., Sparen P., Tryggvadottir L., Munk C., Dasbach E., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 196 10 (2007) 1447-1454
79. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 19 (2007) 1928-1943
80. Gall S.A. Female genital warts: global trends and treatments. Infect Dis Obstet Gynecol 9 3 (2001) 149-154
81. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention 2008. Available at: http://www.cdc.gov/ (last accessed: April 2008).
82. Health Protection Agency. Health Protection Agency, UK 2008 April Available at: http://www.hpa.org.uk/ (last accessed: April 2008).
83. Insinga R.P., Dasbach E.J., and Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36 11 (2003) 1397-1403
84. Insinga R.P., Dasbach E.J., and Elbasha E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 23 11 (2005) 1107-1122
85. Brown R.E., Breugelmans J.G., Theodoratou D., and Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 22 4 (2006) 663-670
86. Dickens P., Srivastava G., Loke S.L., and Larkin S. Human papillomavirus 6, 11, and 16 in laryngeal papillomas. J Pathol 165 3 (1991) 243-246
87. Armstrong L.R., Preston E.J., Reichert M., Phillips D.L., Nisenbaum R., Todd N.W., et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 31 1 (2000) 107-109
88. Lindeberg H. Laryngeal papillomas: histomorphometric evaluation of multiple and solitary lesions. Clin Otolaryngol Allied Sci 16 3 (1991) 257-260
89. Derkay C.S., and Darrow D.H. Recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 115 1 (2006) 1-11
90. Abramson A.L., Nouri M., Mullooly V., Fisch G., and Steinberg B.M. Latent human papillomavirus infection is comparable in the larynx and trachea. J Med Virol 72 3 (2004) 473-477
91. Hobbs C.G., and Birchall M.A. Human papillomavirus infection in the etiology of laryngeal carcinoma. Curr Opin Otolaryngol Head Neck Surg 12 2 (2004) 88-92